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Introduction 
Lipid Nanoparticles are used for efficient drug delivery in 
lung cancer. Just within the United States, it is estimated that 
lung cancer results in as many as 160,000 deaths1-5. Of this, 
non-small cell lung cancers NSLC accounts for an 
approximate 80 percent of a lung cancer situation. 
Compared to small cell lung cancer and other forms of 
cancer, the NSLC form is less responsive to surgery. This 
means that lung cancer can only be targeted using 
chemotherapeutic treatment and radiation. NSLC’s mortality 
percentage and the lack of a surgical treatment means 
chemotherapeutical treatment must be efficient. It is in this 
context that lipid nanoparticles are identified as playing an 
influential role6-12.  
In human lung cancers, the miR-21 or the microRNA-21 is 
upregulated. It is an onco-miR. The antimiR-21 AM21, an 
Oligonucleotide is used complementary to miR-21 for 
inhibiting gene silencing of the miR-21. When used as a 
therapeutic agent, it is found that the antimiR is very 
sensitive to nucleases and is usually cleared faster from 
blood circulation necessitating more drug delivery. A 
therapeutic agent has to be present in the blood circulation 
for a particular time for it to be effective13-19. Additionally, it 
also suffers from its inability to penetrate the cell membrane 
for efficient drug delivery. When they are introduced with 
lipid nanoparticles LNPs, the new formulation is more 
efficient at drug delivery.  
Cheng et al.20 identified a new antisense oligonucleotide with 
chemical modifications and nanoparticle delivery that could 
target tumors and inhibit their growth compared to the use 
of traditional drug delivery of G319. The data suggested that 
the new modified G3139-GAPLNP promoted apoptosis 
better than other formulations. Cheng et al.21 also present 
data on how the existing studies do show much benefit in 
using the lipid nanoparticles. Delivery with lipid 
nanoparticles supposedly increase the nuclease stability and 
hence the biological activity of the drug siRNA is reduced. 
When evaluated in in-vitro and in-vivo studies, it has been 
identified that there is an improvement in the efficacy of 
drug treatment. Similarly, Yung et al.4 identified a novel lipid 
nanoparticle formulation, the QTsome. The QTsome made 
with a quaternary amine, and tertiary amine cationic lipids 
present with a unique pH-responsive profile called the 
QTsome, and this QTsome helped upregulate the miR21 in 
lung cancer22-29.  
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Figure 1: Unique pH profile, at pH value of 7.4 quaternary amine cationic lipids maintain charge for stability. After endocytosis, 
at pH 5.5, endosome membrane interaction/ disruption is promoted4. 
 
The QTsome used in the research work of Yung et al.4 was 
prepared using a serial ethanol dilution method. The final 
concentration of the QTsome was stored at 4-degree Celsius, 
and for long term stability, a 10 percent sucrose solution 
was also added as a cryo-protectant. Mean particle diameter, 
and drug loading and stability aspects were also tested. 
Encapsulation efficiency was evaluated at -20, 4, and 25-
degree Celsius for 30 days. Encapsulation efficiency and the 
colloidal stability of QTsomes were calculated. It was 
identified in-vitro analysis that better upregulation targeting 
of miR-21 happens30-34. The targeting activity is much better 
compared to other formulations that made use of quaternary 
or tertiary amine cationic lipids. Furthermore, the use of 
lipid nanoparticles also led to better stability in the system. 
A stable pH sensitive system is presented here. An additional 
benefit observed is that of the reduced migration and 
invasion of the drug. Cytotoxicity issues are identified in 
drug delivery because of drug leakage issues. Normal tissue 
cells also get affected in addition to the tumor cells. Drug 
dispersion can also result in reduced efficacy of the drug 
treatment as well20,21,35,36. Yung et al.4 thus identified three 
different benefits in the use of lipid nanotechnology for drug 
delivery. In the context of discussing lipid nanoparticles for 
lung cancer, it is also necessary to explain how the use of 
nanoparticles could reduce multidrug resistance. Works on 
other forms of cancer such as brain tumors appear to show a 
multidrug resistance problem, and the use of 
nanotechnology for drug delivery helps control the problem. 
A similar case analysis can also be done concerning lung 
cancer to identify how MDR inhibition is aided in lung 
cancer.  
This literature review attempted to analyze how lipid 
nanoparticles are used in the treatment of lung cancer. The 
research work of Yung et al.4 and Cheng et al.21 identified 
how lipid nanoparticles used for drug delivery help retain 
the drug in blood circulation for the needed time thus 
resulting in better health benefits.  
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